Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study

Aims Sacubitril/valsartan has shown efficacy and tolerability in patients with heart failure (HF) and reduced ejection fraction (HFrEF) in the ambulatory setting (PARADIGM‐HF), and following stabilisation of acutely decompensated HF (ADHF) (PIONEER‐HF and TRANSITION). However, data are lacking for t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of heart failure 2020-02, Vol.22 (2), p.303-312
Hauptverfasser:	Senni, Michele, Wachter, Rolf, Witte, Klaus K., Straburzynska‐Migaj, Ewa, Belohlavek, Jan, Fonseca, Candida, Mueller, Christian, Lonn, Eva, Chakrabarti, Arhit, Bao, Weibin, Noe, Adele, Schwende, Heike, Butylin, Dmytro, Pascual‐Figal, Domingo
Format:	Artikel
Sprache:	eng
Schlagworte:	Aftercare Aminobutyrates - therapeutic use Biphenyl Compounds - therapeutic use de novo Drug Combinations Heart failure Heart Failure - drug therapy Humans Patient Discharge Sacubitril/valsartan Safety Tolerability TRANSITION Valsartan - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!